CAS 319460-85-0: Axitinib
Description:Axitinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of advanced renal cell carcinoma. It selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which play a crucial role in tumor angiogenesis and growth. The chemical formula of Axitinib is C19H18N4O4, and it has a molecular weight of approximately 358.37 g/mol. This compound is characterized by its ability to interfere with the signaling pathways that promote blood vessel formation in tumors, thereby inhibiting tumor growth and metastasis. Axitinib is administered orally and is known for its relatively high bioavailability. Its pharmacokinetics include a moderate half-life, necessitating careful dosing to maintain therapeutic levels. Common side effects may include hypertension, fatigue, and gastrointestinal disturbances. Due to its mechanism of action, Axitinib is classified as an antineoplastic agent and is often used in combination with other therapies to enhance treatment efficacy in cancer patients.
Formula:C22H18N4OS
InChI:InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
InChI key:InChIKey=RITAVMQDGBJQJZ-FMIVXFBMSA-N
SMILES:O=C(NC)C=1C=CC=CC1SC=2C=CC=3C(=NNC3C2)C=CC4=NC=CC=C4
- Synonyms:
- Ag 013736
- Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-
- Inlyta
- N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
- N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide
- N-methyl-2-({3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl}sulfanyl)benzamide
- Axitinib